Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program
29th May 2020
Portfolio
This post references, or is about Harpoon. Find out more by clicking below
Print Article
Email Article
Save Article
